You just read:

Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference

News provided by

Medicenna Therapeutics Corp.

Sep 30, 2019, 07:30 ET